Bird, E. D., Barnes, J., Iversen, L. L., Spokes, E. G., Mackay, A. V. P. & Shepherd, M. (1977). Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet ii, 1157–1159.CrossRefGoogle Scholar

Bird, E. D., Spokes, E. G. S. & Iversen, L. L. (1979). Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102, 347–360.CrossRefGoogle ScholarPubMed

Bowen, D. M., Smith, C. B., White, P. & Davison, A. N. (1976). Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459–496.CrossRefGoogle ScholarPubMed

Bowers, M. B. (1974). Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry 31, 50–54.CrossRefGoogle ScholarPubMed

Bowery, N. G. & Brown, D. A. (1974). Depolarizing actions of γ-amino-butyric acid and related compounds on rat superior cervical ganglia in vitro. British Journal of Pharmacology 50, 205–218.CrossRefGoogle Scholar

Bowery, N. G., Hill, D. R., Hudson, A. L., Doble, A., Middlemiss, D. N., Shaw, J. & Turnbull, M. (1980). (-)baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 283, 92–94.CrossRefGoogle Scholar

Brennan, M. J. W. & Cantrill, R. C. (1979). δ-aminolaevulinic acid is a potent agonist for GABA autoreceptors. Nature 280, 514–515.CrossRefGoogle ScholarPubMed

Brown, D. A. & Marsh, S. (1978). Axonal GABA-receptors in mammalian peripheral nerve trunks. Brain Research 156, 187–191.CrossRefGoogle ScholarPubMed

Carlsson, A. (1978). Antipsychotic drugs, neurotransmitters and schizophrenia. American Journal of Psychiatry 135, 164–173.CrossRefGoogle ScholarPubMed

Casey, D. E., Gerlach, J., Magelund, G. & Christensen, T. R. (1980). γ-acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry 37, 1376–1380.CrossRefGoogle ScholarPubMed

Chouinard, G. & Jones, B. D. (1978). Schizophrenia as dopamine-deficiency disease. Lancet ii, 99–100.CrossRefGoogle Scholar

Collins, G. G. S. (1980). Release of endogenous amino acid neurotransmitter candidates from rat olfactory cortex slices: possible regulatory mechanisms and the effects of pentobarbitone. Brain Research 190, 517–528.CrossRefGoogle ScholarPubMed

Cross, A. J., Crow, T. J. & Owen, F. (1979). Gamma-aminobutyric acid in the brain in schizophrenia. Lancet i, 560–561.CrossRefGoogle Scholar

Crow, T. J. (1978). Schizophrenia. The biochemistry of schizophrenia. British Journal of Hospital Medicine 20, 532–544.Google ScholarPubMed

Crow, T. J., Baker, H. F., Cross, A. J., Joseph, M. H., Lofthouse, R., Longden, A., Owen, F., Riley, G. J., Glover, V. & Killpack, W. S. (1979). Monoamine mechanisms in chronic schizophrenia: post-mortem neuro-chemical findings. British Journal of Psychiatry 134, 249–256.CrossRefGoogle Scholar

Curtis, D. R. (1979). GABA-ergic transmission in the mammalian central nervous system. In GABA-Neurotransmitters (ed. Krogsgaard-Larsen, P., Scheel-Kruger, J. and Kofod, H.), pp. 17–27. Munksgaard: Copenhagen.Google Scholar

Davis, K. E., Hollister, L. E. & Berger, P. A. (1976). Baclofen in schizophrenia. Lancet i, 1245.CrossRefGoogle Scholar

Flor-Henry, P. (1969). Psychosis and temporal lobe epilepsy. Epilepsia 10, 363–395.CrossRefGoogle ScholarPubMed

Gallo, V., Levi, G., Raiteri, M. & Coletti, A. (1981). Enhancement by GABA of glutamate depolarization-induced release from cerebellar nerve endings. Brain Research 205, 431–435.CrossRefGoogle ScholarPubMed

Gerlach, J., Rye, T. & Kristjansen, P. (1978). Effect of baclofen on tardive dyskinesia. Psychopharmacology 56, 145–151.CrossRefGoogle ScholarPubMed

Gold, G. I., Bowers, M. B., Roth, R. H. & Sweeney, D. W. (1980), GABA levels in CSF of patients with psychiatric disorders. American Journal of Psychiatry 137, 362–364.Google ScholarPubMed

Hare, T. A., Manyam, N. V. B. & Glaeser, B. S. (1980). Evaluation of cerebrospinal fluid γ-aminobutyric acid content in neurologic and psychiatric disorders. In Neurobiology of Cerebrospinal Fluid (ed. Wood, J. H.), p. 751. Plenum: New York.Google Scholar

Heath, R. G. (1954). Studies in Schizophrenia. Harvard University Press: Cambridge, Mass.CrossRefGoogle Scholar

Lautin, A., Angrist, B., Stanley, M., Gershon, S., Heckl, K. & Karobath, M. (1980). Sodium valproate in schizophrenia: some biochemical correlates. British Journal of Psychiatry 137, 240–244.CrossRefGoogle ScholarPubMed

Lees, A. J., Shaw, K. M. & Stern, G. M. (1978). Baclofen in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 41, 707–708.CrossRefGoogle ScholarPubMed

Lichtshtein, D., Dobkin, J., Ebstein, R. P., Biederman, J., Rimon, R. & Belmaker, R. H. (1978). Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment. British Journal of Psychiatry 132, 145–148.CrossRefGoogle ScholarPubMed

McCarthy, B. W., Gomes, U. R., Neethling, A. C., Shanley, B. C., Taljaard, J. J. F., Potgieter, L. & Roux, J. T. (1981). γ-Aminobutyric acid concentration in cerebrospinal fluid in schizophrenia. Journal of Neurochemistry 36(4), 1406–1408.CrossRefGoogle ScholarPubMed

McGeer, E. G. & McGeer, P. L. (1979). GABA-containing neurons in schizophrenia, Huntington's chorea and normal aging. In GABA-Neurotransmitters (ed. Krogsgaard-Larsen, P., Scheel-Kruger, J. & Kofod, H.), pp. 340–356. Munksgaard: Copenhagen.Google Scholar

McGeer, P. L., Brown, W. T. & Zeldowicz, L. (1977). Lack of effect of gamma-hydroxybutyrate in Huntington's chorea. Canadian Psychiatric Association Journal 22, 87–89.CrossRefGoogle ScholarPubMed

MacKay, A. V. P. (1980). Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 137, 379–386.CrossRefGoogle ScholarPubMed

Manyam, N. V. B., Katz, L., Hare, T. A., Gerber, J. C. & Grossman, M. H. (1980). Levels of γ-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Archives of Neurology 37, 352–355.CrossRefGoogle ScholarPubMed

Meldrum, B. S. (1975). Epilepsy and γ-aminobutyric acid-mediated inhibition. International Review of Neurobiology 17, 1–36. Academic Press: New York.Google Scholar

Meldrum, B. S. (1979). Convulsant drugs, anticonvulsants and GABA-mediated neuronal inhibition. In GABA-Neurotransmitters (ed. Krogsgaard-Larsen, P., Scheel-Kruger, J. and Kofod, H.), pp. 390–405. Munksgaard: Copenhagen.Google Scholar

Meldrum, B. (1981). Anticonvulsant drugs and GABA-mediated inhibition. In Psychopharmacology of Anticonvulsant drugs (ed. Sandler, M.). Oxford University Press: London.Google Scholar

Meldrum, B., Pedley, T., Horton, R., Anlezark, G. & Franks, A. (1980). Epileptogenic and anticonvulsant effects of GABA agonists and GABA uptake inhibitors. Brain Research Bulletin 5, Supplement 2, 685–690.CrossRefGoogle Scholar

Mitchell, P. R. & Martin, I. L. (1978). Is GABA release modulated by presynaptic receptors? Nature 274, 904–905.CrossRefGoogle ScholarPubMed

Olpe, H. R., Schellenberg, H. & Koella, W. P. (1977). Rotational behaviour induced in rats by intranigral application of GABA-related drugs and GABA antagonists. European Journal of Pharmacology 45, 291–294.CrossRefGoogle ScholarPubMed

Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A. & Riley, G. J. (1978). Increased dopamine-receptor sensitivity in schizophrenia. Lancet ii, 223–226.CrossRefGoogle Scholar

Palfreyman, M. G., Schechter, P. J., Buckett, W. R., Tell, G. P. & Koch-Weser, J. (1981). The pharmacology of GABA-transaminase inhibitors. Biochemical Pharmacology 30, 817–824.CrossRefGoogle ScholarPubMed

Pepplinkuizen, L., Bruinvels, J., Blom, W. & Moleman, P. (1980). Schizophrenia-like psychosis caused by a metabolic disorder. Lancet i, 454–456.CrossRefGoogle Scholar

Perry, T. L., Buchanan, J., Kish, S. J. & Hansen, S. (1979). γ-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet i, 237–239.CrossRefGoogle Scholar

Perry, T. L., Wright, J. M., Hansen, S., Allan, B. M., Baird, P. A. & MacLeod, P. M. (1980). Failure of amino-oxyacetic acid therapy in Huntington's disease. Neurology 30, 772–775.CrossRefGoogle Scholar

Post, R. M., Fink, E., Carpenter, W. T. & Goodwin, F. K. (1975). Cerebrospinal fluid amine metabolites in acute schizophrenia. Archives of General Psychiatry 32, 1063–1069.CrossRefGoogle ScholarPubMed

Randrup, A. & Munkvad, I. (1972). Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomolecular Psychiatry 1, 2–27.Google Scholar

Roberts, E. (1976). Disinhibition as an organizing principle in the nervous system. The role of the GABA system. Application to neurologic and psychiatric disorders. In GABA in Nervous System Function (ed. Roberts, E., Chase, T. N. and Tower, D. B.), pp. 515–539. Raven Press: New York.Google Scholar

Simpson, G. M., Branchey, M. H. & Shrivastana, R. K. (1976). Baclofen in schizophrenia. Lancet i, 966–967.CrossRefGoogle Scholar

Slater, E., Beard, A. W. & Glithero, E. (1963). The schizophrenia-like psychoses of epilepsy. British Journal of Psychiatry 109, 95–150.CrossRefGoogle Scholar

Spokes, E. G. S., Garrett, N. J., Rossor, M. N. & Iversen, L. L. (1980). Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. Journal of Neurological Sciences 48, 303–313.CrossRefGoogle ScholarPubMed

Stevens, J., Wilson, K. & Foote, W. (1974). GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia (Berlin) 39, 105–119.CrossRefGoogle ScholarPubMed

Sweeney, V. P., Pathak, M. A. & Asbury, A. K. (1970). Acute intermittent porphyria. Increased ALA-synthetase activity during an acute attack. Brain 93, 369–380.CrossRefGoogle ScholarPubMed

Tamminga, C. A., Crayton, J. W. & Chase, T. N. (1978). Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry 135, 746–747.Google ScholarPubMed

Tamminga, C. A., Crayton, J. W. & Chase, T. N. (1979). Suppression of involuntary movements in tardive dyskinesia by muscimol, a GABA agonist. Archives of General Psychiatry 36, 595–598.CrossRefGoogle Scholar

Tell, G., Böhlen, P., Schechter, P. J., Koch-Weser, J., Agid, Y., Bonnett, A. M., Coquillat, G., Chazot, G. & Fischer, C. (1981). Treatment of Huntington disease with γ-acetylenic GABA, an irreversible inhibitor of GABA transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology 31, 207–211.CrossRefGoogle ScholarPubMed

Van Kammen, D. P. (1977). γ-aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. American Journal of Psychiatry 134, 138–143.Google ScholarPubMed

Van Praag, H. M. (1977). The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenics. British Journal of Psychiatry 130, 463–474.CrossRefGoogle Scholar

Waser, P. G. (1967). The pharmacology of amanita muscaria.In Ethnopharmacologic Search for Psychoactive Drugs. Proceedings of a Symposium held in San Francisco California,28–30 January 1967 (ed. Efron, D. H., Holmstedt, B. and Kline, N. S.), pp. 419–439.Google Scholar

Wolf, P., Olpe, H. R., Avrith, D. & Haas, H. L. (1978). GABA-ergic inhibition of neurons in the ventral tegmental area. Experientia 34, 73.CrossRefGoogle Scholar

Wood, J. H., Hare, T. A., Glaeser, B. S., Ballenger, J. C. & Post, R. M. (1979). Low cerebrospinal fluid γ-aminobutyric acid content in seizure patients. Neurology 29, 1203–1208.CrossRefGoogle ScholarPubMed

Yde, A., Lohse, E. & Faurbye, A. (1941). On the relation between schizophrenia, epilepsy and induced convulsions. Acta psychiatrica et neurologica scandinavica 16, 325–388.CrossRefGoogle Scholar